Home » Tom Rutkowski

Tom Rutkowski

Principal, Commercial Strategic Planning

Mr. Rutkowski is a Principal in CBPartners' Commercial Planning practice and the Portfolio Optimization Center of Excellence.

Mr. Rutkowski’s healthcare commercial planning and strategic marketing experience spans all stages of product development and a broad range of therapeutic areas, including oncology, cardiovascular, respiratory, and orphan diseases. Project expertise includes BD assessment, clinical plan development, product positioning, patient support services, and core market research (e.g., chart studies, buying processes, ATUs, etc.). A particular point of project emphasis for Mr. Rutkowski is his team’s ability to create a cohesive brand strategy by connecting both physician and payer insights.

Mr. Rutkowski has over a decade of experience in healthcare consulting where he has advised both large biopharma clients with diverse portfolios as well as innovative, single-asset biotech clients. Prior to joining CBPartners, Mr. Rutkowski was a marketing consultant for Publicis Sapient (Healthcare practice). Mr. Rutkowski holds a bachelor's degree from Cornell University with a major in Biological Engineering and a minor in Operation Research and Information Engineering.

Connect with Tom Rutkowski

tom.rutkowski@cbpartners.com

+1 631 398 9102

LinkedIn

Published Articles

Digital Therapeutics as Digital Companions: Models for Effective Pharma Partnerships

Pharma and biotech companies should be prepared to make long-term investments in capability building, market development, and evidence generation to maximize the value of digital companions.

FDA Launches the Digital Health Center of Excellence

Ten Long-term Impacts of COVID-19 on Biopharma

COVID-19 has presented an abundance of short-term implications and challenges for biopharma companies; however, it is useful to understand and prepare for the longer-term impacts as the acute disruptions to regulatory processes and healthcare delivery begin to subside. To proactively prepare for a post-COVID-19 world, biopharma leaders should develop strategies to integrate technology across the value chain and increase focus on patient centricity in terms of process flows and treatment administration.

10 Long-term Impacts of COVID-19 on Biopharma

CBPartners lists the top 10 long-term trends and implications of COVID-19 on the biopharma industry as biopharma leaders prepare for a post-COVID-19 world.

Access and Reimbursement: Access to Digital Therapeutics in a Post-COVID-19 World

CBPartners’ in collaboration with Eric Bernath, explores the current USA access landscape, processes and pitfalls for companion digital therapeutics (DTx), as well as how the space is likely to evolve in the future, and lays out some best practices as suggested by USA payers to maximize chances of reimbursement.

Clinical Trial Disruptions: Can Small-Cap Biopharma Companies Weather the Impact of COVID-19?

Cumulative costs from patient enrollment scenarios due to COVID-19 will likely generate a significant financial drain on biopharma R&D expenditures. CBPartners' blog post investigates this impact and explores mitigation strategies.

8 Commercial Considerations for Tumor-Agnostic Therapies

Tumor-Agnostic Therapies: The Complex Path to Commercial Viability

The tumor-agnostic space is incredibly exciting and an area that is likely to be explored further. CBPartners’ blog post addresses the current precision medicine landscape, touching upon challenges, as well as key commercial considerations.

Applying Technology in Pharma (ATP): Assessment of Investment Trends in Digital Health

VC investment in digital healthcare has been growing rapidly (+42% vs. 2017) as the potential of new technology to solve complex issues, ranging from providing healthcare services to managing chronic conditions, evolves. CBPartners takes a look at investment trends in digital health.

Vermont’s Drug Importation: Rubber, Meet Road

Vermont’s fledgling drug importation law has undergone preliminary savings analysis, with uninspiring projections of a 3.8% drug cost savings rate. CBPartners evaluates the real impact of this new policy.